arct stock — ARCT overview

ARCT (Arcturus Therapeutics Holdings, Inc.) — Stock

Short summary: arct stock is the Nasdaq ticker for Arcturus Therapeutics Holdings, Inc., a clinical-stage mRNA medicines and vaccine company focused on infectious diseases and rare liver/respiratory disorders; this page covers the company, its pipeline, and stock/market information.

Company overview

Arcturus Therapeutics Holdings, Inc. (ARCT) is a clinical-stage biotechnology company that develops mRNA-based medicines and vaccines using proprietary delivery and mRNA chemistry platforms. The company’s core platform technologies include LUNAR (a lipid-mediated delivery system) and STARR (self-transcribing and replicating RNA technology). Headquartered in San Diego, Arcturus was founded in 2013 and positions itself as a developer of therapeutics and prophylactic vaccines across infectious diseases and rare liver and respiratory disorders. arct stock represents public-market exposure to these technology platforms and the company’s progress in clinical development.

Stock identification and trading information

arct stock trades under the symbol ARCT on the Nasdaq exchange. Historically ARCT has been classified in the micro- to small-cap band and is known for relatively high volatility typical of clinical-stage biotech equities that are catalyst-driven. Common market-data sources for quotes and real-time information include Nasdaq, Yahoo Finance, Barchart, Morningstar, and broker/dealer platforms that provide US-listed equity access.

Ticker and exchange

• Ticker symbol: ARCT
• Primary exchange: Nasdaq

Market classification & liquidity

ARCT has typically sat in the micro-/small-cap market-cap band, often in the low hundreds of millions of USD in market capitalization in recent years. As with many biotechnology micro/small-cap stocks, arct stock may show lower liquidity at times and above-average intraday price swings tied to clinical-data or regulatory news.

How to trade/buy

To buy arct stock, use a brokerage account that offers access to US-listed equities. Many retail broker platforms and full-service brokers support Nasdaq-listed stocks; Bitget also provides services for users seeking market access and investment tools. Typical investor tools include watchlists, analyst pages, company investor-relations pages, SEC filings, and news feeds to track announcements and catalysts.

As of 2026-01-27, per Nasdaq and Yahoo Finance reports, ARCT was reported in the low hundreds of millions of USD market-cap range, with average daily trading volume typically ranging from the hundreds of thousands to low millions of shares depending on news flow and market conditions. (Sources: Nasdaq quote pages and Yahoo Finance — reporting dates noted.)

History and corporate timeline

Arcturus was founded in 2013 to develop RNA-based therapeutics and vaccines. Over its corporate history the firm has focused on building delivery and mRNA-engineering capabilities and advancing multiple development candidates into clinical testing. Key high-level milestones typically cited in company disclosures and press releases include the development of the LUNAR delivery platform for systemic and organ-targeted delivery, the introduction of STARR self-replicating RNA constructs for dose-sparing vaccine approaches, initiation of clinical trials for multiple programs, and collaboration or license agreements with third parties for specific programs or technology areas.

Major timeline entries (high-level):

• 2013 — Company founded and initial platform development
• Platform development — LUNAR lipid-delivery system and STARR self-replicating mRNA approach developed and optimized for multiple indications
• Clinical progress — progression of lead programs into Phase 1/2 clinical studies for rare liver disorders and vaccine candidates for infectious diseases
• Regulatory and partnership events — periodic collaborations, grant awards, and regulatory submissions/authorizations in selected jurisdictions as reported in company releases

For precise dates and full historic detail, consult the company’s investor relations materials and SEC filings.

Technology and business model

Arcturus’s technology strategy centers on two complementary mRNA approaches:

• LUNAR: a proprietary lipid-mediated delivery system designed to transport mRNA to target tissues (for example, liver-directed delivery for metabolic or genetic liver conditions). LUNAR’s delivery lipids and formulation chemistry are intended to enable efficient cellular uptake and expression of therapeutic mRNA payloads.

• STARR: a self-transcribing and replicating RNA (replicon) approach that uses engineered RNA constructs to amplify expression inside cells, potentially enabling lower doses for vaccines and therapeutics through in situ RNA replication.

Business model: Arcturus operates as an R&D-led, clinical-stage biotechnology company. Revenue to date has primarily come from collaborations, milestone payments, grants, and limited commercial or sublicense income where applicable. The firm’s value-creation pathway depends on advancing clinical programs, securing regulatory approvals, and/or entering partnerships or licensing deals for development and commercialization of products built on LUNAR and STARR technologies.

Investors typically monitor R&D spend, cash runway, milestone payments, and business-development announcements as indicators of near- and medium-term financing and partnership prospects for arct stock.

Product pipeline and clinical programs

Below is a concise overview of the company’s lead candidates and programs based on public disclosures; program statuses change with ongoing trials and announcements, so consult company press releases and SEC filings for the latest updates.

• ARCT-032 (LUNAR-CF): An mRNA therapeutic candidate designed for cystic fibrosis (CF) using the LUNAR delivery platform to deliver therapeutic mRNA to target tissues. Program development has proceeded through preclinical and early clinical evaluations; refer to company updates for current trial-phase status.

• ARCT-810 (LUNAR-OTC): An mRNA therapeutic intended to treat ornithine transcarbamylase (OTC) deficiency, a rare liver metabolic disorder. The program leverages LUNAR for liver-targeted delivery and has advanced into early-phase clinical testing per company disclosures.

• COVID-19 and influenza vaccine programs: Arcturus has advanced several vaccine candidates leveraging LUNAR and STARR constructs, including LUNAR-COV19 and LUNAR-FLU variants and program identifiers that may appear in public materials (for example, clinical or program numbers reported in company press releases). Historically, vaccine candidates have been developed both for direct company development and in collaboration with partners; regulatory authorizations and country-specific approvals have been reported in past press statements for selected jurisdictions. These programs illustrate the company’s focus on both prophylactic vaccines and therapeutic mRNA treatments.

• Other programs: Arcturus maintains additional preclinical and early-stage efforts to expand its platform utility across target indications, including platform optimization and new payloads. The company’s pipeline typically includes discovery-stage assets, preclinical studies, and early clinical programs intended to demonstrate platform versatility.

Note: arct stock performance is often sensitive to progress updates from these pipeline programs.

ARCT-032 (LUNAR-CF)

ARCT-032 is described by the company as an mRNA approach to address the underlying protein deficiency in some forms of cystic fibrosis. The program uses LUNAR delivery for targeted cellular uptake; public filings and press releases provide trial-phase updates and enrollment information as trials progress.

ARCT-810 (LUNAR-OTC)

ARCT-810 targets ornithine transcarbamylase (OTC) deficiency by delivering mRNA to restore or augment deficient enzyme activity. Development milestones, such as initiation of first-in-human studies or reported safety/tolerability findings, are announced through the company’s investor communications.

COVID-19 and influenza vaccine programs (e.g., LUNAR-COV19, LUNAR-FLU)

Arcturus has developed vaccine constructs for SARS-CoV-2 and influenza using LUNAR and STARR approaches; some programs advanced into clinical testing or were the subject of collaborations. Occasionally, country-specific regulatory actions or authorization-type announcements (stated by the company) have impacted program deployment.

Other programs

Additional preclinical and exploratory programs target other rare diseases and therapeutic areas suitable for mRNA delivery. Pipeline expansion and platform improvements are central to Arcturus’s long-term product strategy.

Clinical trials and regulatory status

Clinical trial results and regulatory milestones are primary value drivers for arct stock. Trial phases (Phase 1, Phase 2, etc.), interim readouts, and regulatory filings materially affect market valuation due to the binary nature of many biotech outcomes. For example, positive tolerability and efficacy signals in early-stage trials can drive substantial share-price appreciation, while negative readouts or safety concerns can cause steep declines. Investors and researchers should consult the company’s press releases, clinicaltrials.gov entries, and SEC filings for the most current trial statuses and regulatory interactions.

As of 2026-01-27, company disclosures and market data providers continued to list active or recently completed early-stage trials across Arcturus’s portfolio; specific phase designations and enrollment metrics are contained in the company’s clinical registries and press materials.

Financial overview

High-level picture: Arcturus, like many clinical-stage biotech companies, has reported revenue from collaborations, milestone receipts, and grants, while historically reporting net losses as R&D and operating expenses outpace revenues until product approvals or commercial launches occur. Key balance-sheet items investors watch include cash on hand, short-term investments, and the company’s disclosed cash runway (often described as the period for which the company can fund operations at current burn rates).

Important financial drivers for arct stock include R&D spending, timing and size of partnership payments, and the company’s ability to manage dilution via equity raises or to secure non-dilutive funding through grants and collaborations.

Key historical/typical metrics

Market-cap and revenue figures change over time and vary by reporting date. Public data providers such as Yahoo Finance, Morningstar, and Nasdaq provide periodic snapshots of market capitalization, share counts, and reported revenue. Analysts and investors commonly track:

• Revenue (quarterly and year-over-year)
• Net loss and EPS (basic/diluted)
• Cash, cash equivalents, and short-term investments
• Quarterly R&D and G&A expense levels
• Cash runway projections disclosed in 10-Q/10-K filings

As of 2026-01-27, market-data sources reported ARCT in the low hundreds of millions USD market-cap band; for up-to-date numeric reporting, consult the company’s latest 10-Q/10-K and market-data pages.

SEC filings & investor relations

Primary financial disclosures for arct stock are the company’s SEC filings (10-Q quarterly reports, 10-K annual reports, and current reports on Form 8-K) and investor-relations materials. These documents provide audited financial statements, management discussion and analysis, and explicit notes on cash position and commitments.

Ownership, analysts, and market sentiment

Institutional ownership in biotech micro/small-cap stocks can vary over time. Public filings sometimes show institutional investors, ETFs, or specialty healthcare funds holding positions in companies like Arcturus; those holdings are reported quarterly in 13F filings and in the company’s SEC reporting. Analyst coverage of arct stock has historically been modest compared with large-cap pharma companies; where coverage exists, consensus ratings and price targets can vary significantly across firms. Retail sentiment—seen on social media and platforms like StockTwits—can also influence intraday flows and volatility.

Notable news, partnerships and events

Market-moving events for arct stock typically include:

• Clinical data readouts and interim analyses
• Regulatory filings, authorizations, or rejections
• Partnership, licensing, or collaboration agreements
• Analyst upgrades/downgrades and fresh coverage
• Financing events (equity raises, convertible notes) affecting dilution and cash runway

To track these events in real time, consult news feeds on market-data sites, the company’s press release page, and SEC 8-K disclosures. As of 2026-01-27, company press releases and market pages continued to be primary sources for material announcements affecting ARCT’s share price.

Risks and considerations

Principal risks for holders or observers of arct stock include clinical and regulatory risk inherent to drug and vaccine development, binary outcomes from trial readouts that can cause large price moves, financing and cash-burn risk if the company needs capital, market liquidity and volatility concerns typical for micro-/small-cap biotech stocks, and competitive or technical risk in the rapidly evolving mRNA therapeutics space.

This article does not provide investment advice; readers should perform their own due diligence and consult professional advisors.

Investment and trading analysis (market perspective)

Market analysts and platforms commonly frame arct stock valuation around several angles: pipeline valuation linked to the probability of technical and regulatory success for lead programs, cash runway and financing needs, potential partnership or licensing deals that could de-risk programs and provide milestones, and near-term clinical catalysts that could move the stock. On some platforms, coverage has shown mixed analyst views ranging from cautious to constructive depending on program progress and financing outlook. Remember that short-term trading in clinical-stage biotech stocks can be highly speculative and catalyst-driven.

Corporate governance and management

Arcturus’s leadership team and board of directors are responsible for corporate strategy, clinical development prioritization, and capital-allocation decisions. For detailed biographies, compensation disclosures, and governance policies, consult the company’s proxy statements and investor-relations materials.

See also

• mRNA therapeutics
• Moderna (as a peer in mRNA vaccine/therapeutics development)
• BioNTech (as a peer in mRNA vaccines)
• Nasdaq biotech sector

References

This article references public market and company information sources. For authoritative and up-to-date data, consult:

• Arcturus investor relations and company press releases (investor relations and press statements)
• SEC filings (10-Q, 10-K, and 8-K reports)
• Nasdaq quote pages (ARCT)
• Yahoo Finance (ARCT quote and historical data)
• Barchart and Morningstar (market metrics and analyst data)
• StockTwits and other retail discussion channels for sentiment indicators
• The Motley Fool and mainstream financial news providers for analysis and coverage

As required for timeliness: As of 2026-01-27, per Nasdaq and Yahoo Finance reporting, ARCT’s market capitalization remained generally in the low hundreds of millions of USD, and average daily trading volume commonly ranged from the hundreds of thousands to the low millions of shares depending on news flow. Please verify current figures with the original sources listed above.

External links

• Official company website and investor relations materials (Arcturus press releases and filings)
• SEC EDGAR filings for Arcturus (10-Q, 10-K)
• Major market-data pages (Nasdaq, Yahoo Finance, Morningstar, Barchart) for live quotes and analyst coverage

Notes on sourcing and currency of facts

Stock prices, market-cap, revenue, trial phases and analyst coverage change frequently. Readers should consult the company’s latest SEC filings, official press releases, and up-to-date market-data providers (Nasdaq, Yahoo Finance, Morningstar, etc.) before making any trading or research decisions.

Disclaimer: This article provides factual and educational information about arct stock and Arcturus Therapeutics and is not investment advice. Always consult registered financial professionals and primary company disclosures when making investment decisions.